Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovail has reported that its subsidiary Biovail Laboratories International, has entered into an exclusive supply agreement with Janssen Pharmaceutica, a division of Johnson & Johnson, for the marketing and distribution of Biovail's once-daily, extended-release formulation of tramadol hydrochloride in 86 countries in two regions - Central and Eastern Europe or Middle East and Latin America.
Subscribe to our email newsletter
Under the terms of this agreement, which has a 10-year term, Biovail will manufacture and supply once-daily extended-release tramadol hydrochloride tablets in dosage strengths of 100mg, 200mg and 300mg to Janssen at contractually determined prices. Janssen affiliates will be responsible for all related promotional costs, as well as all regulatory filings and the management of the regulatory approvals process.
Douglas Squires, interim chairman and CEO of Biovail, said: “This agreement furthers our existing relationship with Ortho-McNeil, an affiliate of Janssen which markets our once-daily tramadol in the US.”